In a dialysis procedure not requiring perfusate addition of acetylcholinesterase inhibitors to "boost" basal levels of acetylcholine (ACh), the influence of the antiparkinson agent piribedil upon levels of ACh in frontal cortex and dorsal hippocampus of freely moving rats was compared with those of other antiparkinson drugs and selective ligands at ␣ 2 -adrenoceptors (ARs). Suggesting a tonic, inhibitory influence of ␣ 2A -ARs upon cholinergic transmission, the ␣ 2 -AR agonist 5-bromo-6-[2-imidazolin-2-yl-amino]-quinoxaline tartrate (UK14,304), and the preferential ␣ 2A
with dopaminergic receptors (Millan et al., 2002; NewmanTancredi et al., 2002a,b) . Notably, several recognize ␣ 2 -ARs. For example, talipexole is an agonist both at D 2 /D 3 receptors and at ␣ 2 -ARs (Meltzer et al., 1989; Millan et al., 2002; Newman-Tancredi et al., 2002a) , whereas piribedil (Jenner, 1995; Smith et al., 2002) behaves as an agonist at D 2 /D 3 receptors yet as an antagonist at ␣ 2A -and ␣ 2C -ARs (Millan et al., 2001 (Millan et al., , 2002 Newman-Tancredi et al., 2002a,b) . Furthermore, in distinction to most other antiparkinson agents, both piribedil and talipexole show negligible affinity for serotonergic receptors (Newman-Tancredi et al., 2002b) . The distinctive profile of piribedil is of considerable interest inasmuch as ␣ 2 -AR antagonists enhance antiparkinson actions of dopaminergic agonists and L-DOPA in rodent and primate models of PD, and suppress the induction of dyskinesias (Brefel-Courbon et al., 1998; Bezard et al., 2001) . These actions may reflect blockade of ␣ 2C -ARs, which are enriched in the striatum Bü cheler et al., 2002) . They also likely reflect blockade of tonically active, inhibitory ␣ 2A -AR autoreceptors on ascending adrenergic neurons, which play an important role in the control of motor behavior, cognition and mood (Kable et al., 2000; Millan et al., 2000; Chopin et al., 2002) . Indeed, degeneration of adrenergic pathways aggravates PD (Sandyk and Iacono, 1990) and, in experimental models, renders subjects more sensitive to dopaminergic neurotoxins (Bing et al., 1994) . In line with these observations, like selective ␣ 2 -AR antagonists, piribedil reinforces ascending adrenergic transmission (Millan et al., 2001) .
The significance of ␣ 2 -AR antagonist properties may not, however, be restricted to an enhancement of adrenergic transmission. The frontal cortex (FCX) receives an intense input from ascending cholinergic projections originating in the nucleus basalis magnocellularis (Amassiri-Teule et al., 1993; Descarries and Umbriaco, 1995) . Together with cholinergic pathways innervating the hippocampus, frontocortical cholinergic projections exert a facilitatory influence upon mnemic processes by the engagement of postsynaptic muscarinic and nicotinic receptors (Broersen et al., 1995; Hironaka et al., 2001) . By analogy to Alzheimer's disease, reduced activity of ascending cholinergic projections contributes to cognitive deficits and the perturbation of mood in parkinsonian patients (Dubois et al., 1986; Sarter and Bruno, 1998; Perry et al., 1999; Reading et al., 2001) . There is ultrastructural evidence that adrenergic and cholinergic projections interact at the terminal level in the cortex and limbic regions (Descarries and Umbriaco, 1995; Li et al., 2001) , whereas adrenergic neurons derived from the locus coeruleus also target cholinergic perikarya (Smiley et al., 1999; Hajszan and Zaborszky, 2002) . Correspondingly, ␣ 2 -ARs are localized in the FCX, hippocampus, and cerebral regions containing cholinergic perikarya Talley et al., 1996) . These observations provide an anatomical substrate for functional interactions among cholinergic and adrenergic pathways (Cuadra and Giacobini, 1995; Niitykoski et al., 1997) and for neurochemical evidence that ␣ 2 -ARs inhibit release of ACh both in the FCX (Moroni et al., 1983; Tellez et al., 1997) and, according to a recent study (Shirazi-Southall et al., 2002) , the hippocampus. However, the identity of the ␣ 2 -AR subtype(s) involved has not been determined and, with few exceptions (Cuadra and Giacobini, 1995; DeBoer and Abercrombie, 1996; Ichikawa et al., 2000 Ichikawa et al., , 2002 , dialysis studies have resorted to AChE inhibitors to "boost" otherwise undetectable basal levels of ACh (Toide and Arima, 1989; Liu and Kato, 1994; Sarter and Bruno, 1998; Shirazi-Southall et al., 2002) .
In light of the above-mentioned observations, we hypothesized that, in analogy to ␣ 2 -AR antagonists, piribedil should reinforce corticolimbic release of ACh in rats. The objectives of this study were, thus, as follows. First, by use of a procedure not requiring the use of AChE inhibitors (Ichikawa et al., 2000 (Ichikawa et al., , 2002 , we characterized the influence of agonists and antagonists possessing contrasting affinities at ␣ 2 -AR subtypes (Table 1) upon extracellular levels of ACh in the FCX of conscious rats. Second, the influence of piribedil upon ACh levels in FCX was compared with the effects of talipexole and of quinelorane, the latter a potent dopaminergic agonist lacking affinity at ␣ 2 -ARs (Table 1; Millan et al., 2002; Newman-Tancredi et al., 2002a,b) . In a parallel experiment, their influence upon extracellular levels of DA in this structure was also examined. Finally, the influence of piribedil, compared with ␣ 2 -AR ligands, upon levels of ACh in the dorsal hippocampus was evaluated.
Materials and Methods
Animals. Male Wistar rats (Iffa Credo, l'Arbresle, France) of 225 to 250 g were allowed free access to food and water and housed singly. Laboratory temperature was 21 Ϯ 1°C and humidity 60 Ϯ 5%. There was a 12-h light/dark cycle (lights on at 7:30 AM). All animal use procedures conformed to international European ethical standards (86/609-EEC) and the French National Committee (décret 87/848) for the care and use of laboratory animals. Dialysis Procedure. Surgery was performed under pentobarbital anesthesia (60 mg/kg i.p.). As described previously (Millan et al., 2001) , rats were mounted in a Kopf stereotaxic frame and a single guide cannulae (CMA/11) implanted in the FCX or dorsal hippocampus with coordinates as follow: AP, ϩ2.2; L, 0.6; DV, Ϫ0.2; or AP, Ϫ3.8; L, 2.0; DV, Ϫ2.0, respectively. Rats were single-housed and allowed to recover for 5 days before dialysis. On the day of dialysis, Ichikawa et al. (2000) . Twenty-microliter dialysate samples were collected on 10 l of 0.01% acetic acid. Twenty-microliter aliquots were then analyzed by high-performance liquid chromatography. The mobile phase was composed of 50 mM Na 2 HPO 4 and 0.5% proclin (BAS, Congleton, UK), adjusted to pH 8.2 with H 3 PO 4 . The stationary phase was comprised of a cation ion exchanger (Sepstik, 530 ϫ 1.0 mm, particle size 10 m; BAS), a precolumn (preimmobilized enzyme reactor, 55 ϫ 1 mm) of choline oxydase/catalase (BAS), and a postcolumn (postimmobilized enzyme reactor, 50 ϫ 1 mm) of choline oxydase/ AChE (BAS) maintained at 35°C. An amperometric detector (LC-4B; BAS) was used for quantification. The electrode was set at ϩ100 mV versus Ag/AgCl. The glassy carbon electrode (MF2098, BAS) was coated with the peroxidase-redox polymer. The mobile phase was delivered at a flow rate of 0.14 ml/min. The sensitivity of the essay for ACh was 0.1 pg (0.55 fmol) (injected in a volume of 20 l). DA levels were quantified by high-performance liquid chromatography followed by coulometric detection as described previously (Millan et al., 2001 ). The assay limit of sensitivity was 0.1 pg/sample. Data were analyzed by ANOVA with sampling time as the repeated within-subject factor.
Chemicals and Drugs. All drugs were injected s.c. in a volume of 1.0 ml/kg. Drugs were dissolved in sterile water plus a few drops of lactic acid if necessary and the pH adjusted to Ͼ5.0. Guanabenz base, quinelorane 2HCl, 2(2-methoxy-1,4 benzodioxan-2-yl)-2-imidazoline HCl (RX821002), prazosin HCl and talipexole 2HCl were purchased from Sigma Chemie (Chesnes, France). Atipamezole HCl, piribedil monomethane sulfonate (Trivastal), 5-bromo-6-[2-imidazolin-2-yl-amino]-quinoxaline tartrate (UK14,304), trans-2, 3,9,13b- 
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Influence of ␣ 2 -AR Agonists and Antagonists upon Dialysis Levels of ACh in the FCX of Freely Moving
Rats. In the absence of AChE inhibitors, basal dialysate levels of ACh were 2.18 Ϯ 0.38 pg/20 l (12 Ϯ 2 fmol/20 l) (Fig. 1 ). As shown in Fig. 2 , the injection of vehicle (1 ml/kg) induced a significant, although modest and transient (20 min), increase in extracellular levels of ACh in the FCX. The ␣ 2 -AR receptor agonist UK14,304 induced a pronounced and dose-dependent (0.16 -2.5 mg/kg s.c.) decrease (maximal effect, Ϫ82 Ϯ 3% versus basal values) in ACh levels ( Fig. 2) , an action mimicked by the preferential ␣ 2A -AR agonist guanabenz (0.16 -10.0 mg/kg s.c.) (maximal effect, Ϫ69 Ϯ 3% versus basal values), although with a less sustained duration of action (Fig. 3) . In contrast, the selective ␣ 2 -AR antagonists atipamezole (0.63-630 g/kg s.c.) and RX821002 (0.01-2.5 mg/kg s.c.), dose dependently elevated levels of ACh, with peak effects of ϩ168 Ϯ 26 and ϩ130 Ϯ 40%, respectively (Fig.  2) . Likewise, the selective ␣ 2A -AR antagonist BRL44408 (2.5-40.0 mg/kg s.c.) markedly elevated levels of ACh (maximal effect, ϩ115 Ϯ 15% versus basal values). In contrast, BRL41992 (10.0 mg/kg s.c.), a preferential ␣ 2B/2C -AR antagonist, and prazosin (10.0 mg/kg s.c.), a preferential antagonist at ␣ 2B/2C -ARs (and a potent ␣ 1 -AR antagonist), were inactive ( Fig. 3) .
Influence of Single Doses of Piribedil, Talipexole, and Quinelorane upon Dialysis Levels of DA Compared with ACh in the FCX of Freely Moving Rats. In an initial study, we examined the influence of single, equieffective doses of piribedil, talipexole, and quinelorane upon dialysis levels of DA in FCX. Reflecting their agonist properties at D 2 /D 3 autoreceptors (Millan et al., 2000) , they all elicited marked and significant decreases in frontocortical levels of DA with comparable maximal effects of Ϫ49 Ϯ 9, Ϫ55 Ϯ 10, and Ϫ50 Ϯ 8% versus basal values, respectively (Fig. 4) . At these equivalent doses, it can be seen from Fig. 4 that piribedil elicited a pronounced and significant elevation in ACh levels in FCX, whereas talipexole, in an opposite manner, reduced levels of (1, 5, and 10 pg) of ACh were injected onto the column using chromatographic conditions as described under Materials and Methods. The retention time of ACh was 7.8 min. B, 20 l of a 20-l basal microdialysis sample plus 10 l of acetic acid 0.01% was injected onto the column. In a representative, basal, frontocortical dialysate sample, the quantity of ACh was 1.9 pg. The administration of piribedil (10.0 mg/kg s.c.) increased FCX dialysate levels of ACh to a peak of ACh of 5.9 pg.
ACh; quinelorane did not significantly modify ACh levels. Thus, despite a common, suppressive influence upon DA levels, piribedil, talipexole, and quinelorane differentially modified extracellular levels of ACh in FCX.
Dose-Dependent Influence of Piribedil Compared with Talipexole upon Dialysis Levels of ACh in the FCX of Freely Moving Rats.
In subsequent studies, it was found that piribedil elicited a dose-dependent (0.63-40.0 mg/kg s.c.), Fig. 2 . Influence of the ␣ 2 -AR agonist UK14,304 and of the ␣ 2 -AR antagonists atipamezole and RX821002 upon dialysis levels of acetylcholine in the frontal cortex of freely moving rats. A, UK14,304. B, atipamezole. and C, RX821002. Data are means Ϯ S.E.M. In the frontal cortex, basal levels of ACh were 2.18 Ϯ 0.38 pg/20 l. ANOVA data are as follows: UK14,304 (0.16; n ϭ 5) F(1,9) ϭ 2.9, P Ͼ 0.05; UK14,304 (0.63; n ϭ 5) F(1,9) ϭ 5.2, P Ͻ 0.05; UK14,304 (0.63; n ϭ 5) F(1,9) ϭ 59.4, P Ͻ 0.01; atipamezole (0.00063; n ϭ 5) F(1,9) ϭ 0.3, P Ͼ 0.05; atipamezole (0.01; n ϭ 6) F(1,10) ϭ 2.7, P Ͼ 0.05; atipamezole (0.16; n ϭ 6) F(1,10) ϭ 19.8, P Ͻ 0.01; atipamezole (0.63; n ϭ 6) F(1,10) ϭ 27.6, P Ͻ 0.01; RX821002 (0.01; n ϭ 5) F(1,9) ϭ 0.1, P Ͼ 0.05; RX821002 (0.04; n ϭ 5) F(1,9) ϭ 6.4, P Ͻ 0.05; RX821002 (0.16; n ϭ 6) F(1,10) ϭ 45.9, P Ͻ 0.01; and RX821002 (2.5; n ϭ 6) F(1,10) ϭ 5.2, P Ͻ 0.05. Asterisks indicate significance of drug-treated versus vehicle-treated (n ϭ 6) values. ‫,ء‬ P Ͻ 0.05. Fig. 3 . Influence of the ␣ 2A -AR agonist guanabenz, the ␣ 2A -AR antagonist BRL44408, and the preferential ␣ 2B/2C -AR antagonists BRL41992 and prazosin upon dialysis levels of acetylcholine in the frontal cortex of freely moving rats. A, guanabenz. B, BRL44408. C, prazosin. Data are means Ϯ S.E.M. ANOVA data are as follows: guanabenz (0.16; n ϭ 7) F(1,11) ϭ 0.4, P Ͼ 0.05; guanabenz (2.5; n ϭ 6) F(1,10) ϭ 11.9, P Ͻ 0.01; guanabenz (10.0; n ϭ 5) F(1,9) ϭ 43.4, P Ͻ 0.01; BRL44408 (2.5; n ϭ 5) F(1,9) ϭ 0.6, P Ͼ 0.05; BRL44408 (10.0; n ϭ 6) F(1,10) ϭ 5.7, P Ͻ 0.05; BRL44408 (40.0; n ϭ 7) F(1,11) ϭ 28.3, P Ͻ 0.01; prazosin (10.0; n ϭ 6) F(1,10) ϭ 0.3, P Ͼ 0.05; and BRL41992 (10.0; n ϭ 5) F(1,9) ϭ 0.1, P Ͼ 0.05. Asterisks indicate significance of drug-treated versus vehicle-treated (n ϭ 6) values. ‫,ء‬ P Ͻ 0.05. pronounced, and sustained increase in dialysis levels of ACh (maximal effect, ϩ219 Ϯ 24% versus basal values) (Fig. 5) . In distinction, talipexole provoked a dose-dependent (0.63-10.0 mg/kg s.c.) reduction in extracellular levels of ACh (maximal effect, Ϫ79 Ϯ 5% versus basal values) (Fig. 5) . After pretreatment with a maximally effective dose of RX821002 (2.5 mg/kg s.c.), piribedil (10.0 mg/kg s.c.) failed to significantly modify levels of ACh. This lack of "additive" or "synergistic" effects indicates that they act at a common site. The inhibitory influence of talipexole (10.0 mg/kg s.c.) upon ACh levels was further "canceled out" by pretreatment with RX821002 (Fig. 5) .
Influence of Piribedil Compared with RX821002 and UK14,304 upon Dialysis Levels of ACh in the Dorsal Hippocampus of Freely Moving Rats. Whereas the ␣ 2 -AR agonist UK14,304 (2.5 mg/kg s.c.) markedly suppressed dialysis levels of ACh in dorsal hippocampus, they were elevated by the ␣ 2 -AR antagonist RX821002 (2.5 mg/kg s.c.) (maximal effects, Ϫ71.9 Ϯ 6.7 and ϩ 122.0 Ϯ 27.0% versus basal values, respectively) (Fig. 6) . In analogy to the FCX, piribedil elicited a dose-dependent (2.5-40.0 mg/kg s.c.) and sustained increase in dialysis levels of ACh (maximal effect, ϩ126.7 Ϯ 33.0% versus basal values) (Fig. 6 ).
Discussion
Technical Considerations: Muscarinic Modulation of Frontocortical Release of ACh. Owing to the high capacity and rapid kinetics of AChE, extracellular levels of ACh are greatly (ϳ1000-fold) exceeded by those of its metabolite, choline. This renders detection of extracellular levels of ACh difficult and has necessitated addition of AChE inhibitors to dialysis perfusates. In contrast, corroborating the work of Ichikawa et al. (2000 Ichikawa et al. ( , 2002 , introduction of a supplementary, choline oxydase-loaded, "enzyme-immobilized" column before the "analytical" column eliminated choline from the chromatogram; thus, the fidelity and sensitivity of 
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ACh detection was substantially improved. Accordingly, even "resting" levels of ACh could be reproducibly quantified and values of 2.18 Ϯ 0.38 pg/20 l (15.0 Ϯ 2.6 fmol/20 l) correspond well to those of Ichikawa et al. (2000 Ichikawa et al. ( , 2002 (19.5 Ϯ 0.7 fmol/20 l). They are considerably (Ͼ20-fold) lower than "basal" levels generated in the presence of AChE inhibitors (Cuadra and Giacobini, 1995; Tellez et al., 1997) . Furthermore, the AChE inhibitor, eserine, increased ACh levels by ϳ7-fold (A. Gobert and M. J. Millan, unpublished observation) in line with its pronounced increase in ACh levels upon local perfusion (Ichikawa et al., 2002) . In an extension of the work of Ichikawa et al. (2002) , we demonstrate herein that this technique also permits the reliable detection and quantitation of ACh levels in dorsal hippocampus. In this structure, basal levels of ACh herein, 1.30 Ϯ 0.16 pg/20 l (9.0 Ϯ 1.0 fmol/20 l), were substantially lower than those documented using AChE inhibitors (e.g., 860 fmol/36 l with 0.3 M neostigmine; Shirazi-Southall et al., 2002) .
Quantification of ACh levels in the absence of AChE inhibitors avoids potentially misleading effects due to pharmacological or metabolic interactions with the drug under study (DeBoer and Abercrombie, 1996; Ichikawa et al., 2000 Ichikawa et al., , 2002 . Furthermore, inasmuch as ACh exerts a tonic, inhibitory feedback upon its own release via muscarinic autoreceptors (Zhang et al., 2002) , an elevation in its levels by inhibition of AChE directly modifies actions of agonists and antagonists at these sites (Toide and Arima, 1989; Liu and Kato, 1994; Ichikawa et al., 2002) . In addition, for all drug classes, the apparent magnitude of their actions relative to basal values will be distorted by the use of AChE inhibitors.
By analogy to Ichikawa et al. (2000) , in vehicle-treated rats, levels of ACh in FCX were transiently increased relative to basal values. Similarly, levels of ACh in dorsal hippocampus displayed a short-lived increase upon vehicle injection (Shirazi-Southall et al., 2002) . These responses reflect arousal and cognitive-attentional factors associated with handling and motor activity (Sarter and Bruno, 2000; Giovannini et al., 2001; Hironaka et al., 2001) .
␣ 2 -AR Modulation of Frontocortical Release of ACh. The finding that the ␣ 2 -AR agonist UK14,304 and the ␣ 2 -AR antagonists atipamezole and RX821002, respectively, suppressed and enhanced frontocortical ACh release demonstrates that ␣ 2 -ARs exert a tonic, inhibitory influence upon ACh release in the FCX of conscious rats. This observation amplifies findings of in vitro studies (Williams and Reiner, 1993) and in vivo studies using AChE inhibitors (Moroni et al., 1983; Tellez et al., 1997) . Furthermore, ACh release was reduced by the preferential ␣ 2A -AR agonist guanabenz and accelerated by the selective ␣ 2A -AR antagonist BRL44408 (Young et al., 1989; Renouard et al., 1994) , suggesting a role for the ␣ 2A -AR subtype in this effect. Indeed, prazosin, which displays higher affinity at ␣ 2B/2C -versus ␣ 2A -ARs , did not modify ACh levels, in line with a study of Acquas et al. (1998) . This observation was underpinned by the lack of effect of a further preferential antagonist at ␣ 2B/2C -versus ␣ 2A -ARs, BRL41992 (Young et al., 1989 ), upon ACh levels. Notably, RX821002 does not interact with imidazoline receptors, which cannot, therefore, be implicated in its induction of ACh release. This pattern of effects resembles studies of frontocortical release of noradrenaline and DA and suggests that ␣ 2A -ARs are inhibitory to ACh release (Kable et al., 2000; Millan et al., 2000) , consistent with their high density in the FCX and localization on cholinergic cell bodies (Zaborszky et al., 1995; Talley et al., 1996) . The doses of BRL44408 used herein were shown to block ␣ 2A -ARs in previous investigations including, for example, the modulation of frontocortical release of DA and noradrenaline under conditions analogous to the present study of ACh release Gobert et al., 1998) . Furthermore, the preferential ␣ 2B/2C -AR antagonists BRL41992 and prazosin were used herein at doses previously demonstrated to not block ␣ 2A -ARs Gobert et al., 1998) . However, there is no currently well defined functional model of the role of cerebral ␣ 2B -and/or ␣ 2C -ARs appropriate to the precise definition of their active dose ranges at these sites. Thus, it is necessary to be cautious as regards the apparent exclusion of a role of ␣ 2B -and/or ␣ 2C -ARs in the modulation of ACh release. Indeed, in would be of interest to undertake complementary studies in genetically transformed mice lacking (or overexpressing) specific subtypes of ␣ 2 -AR to corroborate the present observations. Such an approach indicated that ␣ 2C -ARs also, albeit to a minor degree relative to their ␣ 2A -AR counterparts, modulate cerebral monoaminergic transmission (Kable et al., 2000; Bü cheler et al., 2002) .
Facilitatory Influence of Piribedil upon Frontocortical Levels of ACh. Piribedil, which displays marked antagonist properties at ␣ 2A -and ␣ 2C -ARs (Millan et al., 2001 (Millan et al., , 2002 Newman-Tancredi et al., 2002a) , provoked a rapid, dose-dependent and sustained increase in extracellular levels of ACh in FCX. There are several possible explanations for this finding.
First, piribedil might interact directly with muscarinic mechanisms. However, it shows negligible affinity for cloned human M 2 receptors, other (M 1 , M 3 , and M 4 ) muscarinic sites, and for AChE (M. J. Millan, unpublished observation). On structural grounds, it is unlikely that metabolites of piribedil would interact with muscarinic mechanisms: in line with this contention, piribedil does not modify muscarinic responses in vivo (M. J. Millan, unpublished observation). Second, a role of D 2 and/or D 3 receptors might be evoked. However, D 2 /D 3 agonists, such as quinpirole, did not increase ACh release in FCX in a previous study (Day and Fibiger, 1993) . Accordingly, the potent D 2 /D 3 agonist quinelorane, which is devoid of affinity for ␣ 2 -ARs, failed to modify dialysis levels of ACh and several other selective D 2 /D 3 agonists also do not enhance ACh levels (A. Gobert, unpublished observation) . Furthermore, this hypothesis cannot accommodate the opposite facilitatory and inhibitory influence of piribedil and talipexole upon ACh levels, respectively, despite their mutual agonist properties at D 2 /D 3 receptors. Indeed, at doses that elicited an equivalent reduction in FCX release of DA (reflecting activation of D 2 /D 3 autoreceptors), piribedil, talipexole, and quinelorane exerted contrasting influences (increase, decrease, and no change, respectively) upon dialysis levels of ACh (Fig. 4) . Third, the weak antagonist properties of piribedil at ␣ 1 -ARs (Millan et al., 2002; Newman-Tancredi et al., 2002a ) are unlikely to be implicated because they are shared by talipexole, whereas prazosin (a potent ␣ 1 -AR antagonist) did not enhance ACh release in FCX.
Thus, in line with above-discussed evidence for a tonic, inhibitory influence of ␣ 2 -AR heteroceptors upon frontocortical cholinergic transmission, the induction of ACh release in FCX by piribedil likely reflects its antagonist properties at ␣ 2 -ARs. This interpretation accounts for the opposite suppressive influence of talipexole, an agonist at ␣ 2 -ARs (Millan et al., 2002; Newman-Tancredi et al., 2002a) , upon ACh levels. Moreover, in the presence of a maximally effective dose of RX821002, piribedil failed to elevate ACh levels, indicating a common site of action, whereas the inhibitory influence of talipexole was canceled out by pretreatment with RX821002. Further supporting a role of ␣ 2 -ARs, the dose range of piribedil that elevated FCX levels of ACh was identical to that which augments frontocortical levels of noradrenaline by blockade of ␣ 2A -ARs (Millan et al., 2001) . Although blockade of the ␣ 2A -AR subtype likely participates in the influence of piribedil upon ACh release (vide supra), this issue remains to be directly addressed. Moreover, inasmuch as ␣ 2 -ARs inhibit ACh release at both the cortical and dendritic level (Moroni et al., 1983; Bertorelli et al., 1991 ), the precise locus(i) of action of piribedil will require future evaluation.
Facilitatory Influence of Piribedil upon Dorsal Hippocampus Levels of ACh. Although the ␣ 2 -AR antagonist yohimbine increased extracellular levels of ACh in the ventral hippocampus of rats, it is poorly selective for ␣ 2 -ARs (Millan et al., 2000) and that study used AChE inhibitors in the dialysate perfusate (Shirazi-Southall et al., 2002) . It is thus of interest that using the present procedure, UK14,304 and RX821002, respectively, decreased and enhanced extracellular levels of ACh in the dorsal hippocampus. This observation provides further evidence for a tonic, inhibitory influence of ␣ 2 -ARs upon ACh release in the dorsal hippocampus, a structure in which their density is particularly high . Correspondingly, reflecting its antagonist properties at ␣ 2 -ARs, piribedil dose dependently elevated dialysis levels of ACh in the dorsal hippocampus, a finding paralleling its actions in the FCX.
General Considerations. First, the present study exploited a technique developed by Ichikawa et al. (2000 Ichikawa et al. ( , 2002 in freely moving rats that does not require systemic or local administration of drugs to artificially elevate basal values of ACh. This strategy, analogous to that used for evaluation of extracellular levels of monoamines (Gobert et al., 1998; Millan et al., 2000) , should prove invaluable in the characterization of the modulation of cerebral cholinergic transmission by psychotropic agents.
Second, piribedil, via its distinctive antagonist properties at ␣ 2 -ARs (Millan et al., 2001 (Millan et al., , 2002 , reinforced frontocortical and hippocampal cholinergic transmission. This action may well contribute to its enhancement of cognitive-attentional function (Maurin et al., 2001; Nagaraja and Jayashree, 2001; Smith et al., 2002) . Indeed, although behavioral studies are required to underpin this contention, there is preliminary evidence that AChE inhibitors exert a favorable influence upon cognitive function in parkinsonian patients (Reading et al., 2001) . Inasmuch as piribedil (like other ␣ 2 -AR antagonists) also enhances noradrenaline release in FCX (Millan et al., 2001) , the relative contribution of cholinergic versus adrenergic mechanisms to its influence upon cognitive-attentional function will be of interest to evaluate.
Third, frontocortical cholinergic pathways also influence motor function, anxiety, sleep and mood (Perry et al., 1999; Sarter and Bruno, 2000; Giovannini et al., 2001; Ichikawa et al., 2002) . Thus, a broader exploration of the functional significance of an increase in FCX release of ACh to the management of PD would be justified. Notably, deficits in cholinergic (frontocortical and pedunculopontine) transmission are implicated in the perturbation of sleep and hallucinations experienced by parkinsonian patients (Perry et al., 1999; Sarter and Bruno, 2000) . Furthermore, AChE inhibitors have been reported to ameliorate psychotic symptoms in patients in PD (Reading et al., 2001; Bergman and Lerner, 2002) .
Finally, although their pronounced side effects (including disruption of sleep and induction of psychosis and cognitive deficits; c.f., paragraphs above) greatly limit their use, muscarinic antagonists have been used in the treatment of PD, principally in the management of refractory tremor and severe L-DOPA-induced dyskinesias (Hurtig, 1997; Wilms et al., 1999; Jenner, 2000; Singer, 2002) . These actions do not reflect their blockade of autoreceptors (thereby enhancing ACh release), rather antagonism of postsynaptic sites in the striatum. Furthermore, D 2 receptors exert an inhibitory influence upon ACh release in the striatum (Di Chiara et al., 1994; DeBoer and Abercrombie, 1996) . In the light of these comments, an interesting question concerns the influence of piribedil compared with other agents upon the striatal release of ACh. In fact, there is no evidence for a role of ␣ 2 -ARs in the control of striatal cholinergic transmission, so its influence upon ACh release therein should not, in principle, differ from those of talipexole, quinelorane, or other agents. This remains to be directly demonstrated. In any case, notwithstanding possible benefits of increased corticolimbic release of ACh in the control of cognitive-attentional function (vide supra), such actions would not be expected to markedly modify the motor symptoms of PD per se.
Conclusions. Using an innovative dialysis approach not requiring use of AChE inhibitors, the present study demonstrates that the antiparkinson agent piribedil, which possesses marked antagonist properties at ␣ 2 -ARs, markedly enhances release of ACh in the FCX and dorsal hippocampus of freely moving rats. These actions may be distinguished to the inhibitory influence of talipexole, which acts as an agonist at ␣ 2 -ARs, and to the lack of effect of quinelorane, which does not interact with ␣ 2 -ARs. A reinforcement of frontocortical cholinergic transmission may contribute to the facilitatory influence of piribedil upon cognitive-attentional function, which is compromised in PD, although it would not be expected to modify motor performance per se. Thus, the present data encourage additional neurochemical, behavioral, and clinical studies of the functional significance of cholinergic transmission and its modulation by ␣ 2 -ARs to the etiology and management of PD.
